Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (2016 - 2022)

Historic Shares Outstanding for Agios Pharmaceuticals (AGIO) over the last 11 years, with Q2 2022 value amounting to $71.0 million.

  • Agios Pharmaceuticals' Shares Outstanding rose 89.06% to $71.0 million in Q2 2022 from the same period last year, while for Jun 2022 it was $71.0 million, marking a year-over-year increase of 89.06%. This contributed to the annual value of $70.6 million for FY2021, which is 181.36% up from last year.
  • According to the latest figures from Q2 2022, Agios Pharmaceuticals' Shares Outstanding is $71.0 million, which was up 89.06% from $71.0 million recorded in Q1 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Shares Outstanding peaked at $71.0 million during Q2 2022, and registered a low of $57.5 million during Q1 2018.
  • For the 5-year period, Agios Pharmaceuticals' Shares Outstanding averaged around $65.3 million, with its median value being $68.9 million (2020).
  • Its Shares Outstanding has fluctuated over the past 5 years, first soared by 1923.66% in 2018, then skyrocketed by 89.06% in 2022.
  • Agios Pharmaceuticals' Shares Outstanding (Quarter) stood at $58.2 million in 2018, then increased by 17.49% to $68.4 million in 2019, then rose by 1.31% to $69.3 million in 2020, then rose by 1.81% to $70.6 million in 2021, then rose by 0.68% to $71.0 million in 2022.
  • Its Shares Outstanding stands at $71.0 million for Q2 2022, versus $71.0 million for Q1 2022 and $70.6 million for Q4 2021.